Skip to content

The Effect of Nordic Walking for Improving Walking Ability in Patients with Peritoneal Dialysis : a Randomized Controlled Trial

The Effect of Nordic Walking for Improving Walking Ability in Patients with Peritoneal Dialysis : a Randomized Controlled Trial - The Effect of Nordic Walking in Peritoneal Dialysis Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052466
Enrollment
30
Registered
2023-10-12
Start date
2023-07-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with peritoneal dialysis

Interventions

Nordic walking for 20-30 minutes more than three times a week. Exercise intensity is decided by two points. One is Borg Scale, of which target score is 11-13. The other is pulse rate of 20-30 bpm high

Sponsors

Japanese Red Cross Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Outpatients with peritoneal dialysis 2) Patients who meet the criteria of sarcopenia(defined by walking speed, grip strength, and skeletal mass index). 3) Patients who have pains of locomotor. 4) Patients from whom we can obtain informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients who are contraindicated for exercise training. Concrete criteria are as follows: patients with uncontrolled persistent hypertension (systolic blood pressure >= 180 mmHg or diastolic pressure >= 110 mmHg); severe anemia (Hb < 7 g/dL); active proliferative diabetic retinopathy; prior symptomatic coronary artery or cerebrovascular diseases within the previous 3 months; uncontrolled heart failure (NYHA >= III); symptomatic or lethal arrhythmia; severe valvular diseases; and walking difficulty due to orthopedic, cerebrovascular and peripheral artery diseases. 2) Unstable PD patients. Concrete criteria are as follows: patients who undergo PD less than 3 months and those with uncontrolled uremia (BUN > 100 mg/dL, K > 6.0 mEq/L and HCO3 < 18 mmoL/L). 3) Patients deemed inadequate for monitoring during study period, as determined by investigators.

Design outcomes

Primary

MeasureTime frame
Six-minute walk test as an index of aerobic capacity in 12 weeks after assignment.

Secondary

MeasureTime frame
Evaluation factors of sarcopenia (walking speed, grip strength, and skeletal mass index), ABI/PWV, body composition index, CKD-related parameters (serum Na/K/Cl, Ca/P/PTH intact, UA, TC/HDL/TG, Hb, carnitine), residual kidney function, Numerical Rate Scale of locomotor, evaluated 12 weeks after assignment.

Countries

Japan

Contacts

Public ContactSumura Rena

Japanese Red Cross Medical Center DIvision of Nephorology

r.sumura1118@gmail.com03-3400-1311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026